Wide Ranks

GDTC

CytoMed Therapeutics Limited

2.31

Top Statistics
Market Cap 26 M Forward PE -13.59 Revenue Growth -21.10 %
Current Ratio 21.53 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -6.49 Enterprise / Revenue 45.26 Price To Sales Trailing12 Months 59.54
Profitability
Profit Margins 0.00 % Operating Margins -735.97 %
Balance Sheet
Total Cash 6 M Total Cash Per Share 0.5910 Total Debt 428285
Total Debt To Equity 4.21 Current Ratio 21.53 Book Value Per Share 0.8810
All Measures
Short Ratio 389.00 % Message Board Id finmb_647650276 Shares Short Prior Month 116076
Return On Equity -0.2626 City Singapore Uuid 5fbb5a07-c64c-3457-b39c-0446de45b69d
Previous Close 1.93 First Trade Date Epoch Utc 1 B Book Value 0.8810
Total Debt 428285 Volume 3042 Price To Book 2.62
Fifty Two Week Low 1.20 Total Cash Per Share 0.5910 Total Revenue 447695
Shares Short Previous Month Date 1 B Target Median Price 5.00 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -735.97 % Target Mean Price 5.00
Net Income To Common -3063187 Short Percent Of Float 0.0450 Implied Shares Outstanding 12 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 6330
Average Volume10days 6330 Total Cash 6 M Next Fiscal Year End 1 B
Revenue Per Share 0.0390 Held Percent Insiders 0.6927 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.93
Target Low Price 5.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.13
Open 2.25 Free Cashflow -2590626 Dividend Yield 0.00 %
Return On Assets -0.1744 Time Zone Short Name EST Trailing Eps -0.2200
Day Low 2.07 Address1 1 Commonwealth Lane, No. 08-22 Shares Outstanding 11 M
Price Hint 4 Target High Price 5.00 Website https://w2.cytomed.sg
52 Week Change -0.3740 Average Volume 12320 Forward Eps -0.1500
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 1919.90 %
Is_sp_500 False Regular Market Day High 2.35 Profit Margins 0.00 %
Debt To Equity 4.21 Fifty Two Week High 5.50 Day High 2.35
Shares Short 76802 Regular Market Open 2.25 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 45.26 Revenue Growth -21.10 %
Shares Percent Shares Out 0.0067 Operating Cashflow -2555008 Currency USD
Time Zone Full Name America/New_York Market Cap 26 M Is_nasdaq_100 False
Zip 149544 Quote Type EQUITY Industry Biotechnology
Long Name CytoMed Therapeutics Limited Regular Market Day Low 2.07 Held Percent Institutions 0.0004
Current Price 2.31 Enterprise To Ebitda -6.49 Financial Currency SGD
Current Ratio 21.53 Gross Margins 100.04 % Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country Singapore Float Shares 3 M
Two Hundred Day Average 2.02 Enterprise Value 20 M Price To Sales Trailing12 Months 59.54
Forward PE -13.59 Regular Market Volume 3042 Ebitda -3120472
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.

Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.

It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore.

The company was incorporated in 2018 and is headquartered in Singapore.